Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial

4 Nov 2024

Abstract excerpt

PURPOSE: Neoadjuvant immunochemotherapy (NAIC) markedly induces pathologic regression in locally advanced gastric adenocarcinoma. However, specific biomarkers are still lacking to effectively identify the beneficiary patients for NAIC. PATIENTS AND METHODS: A prospective, single-arm, phase II study was conducted to treat locally advanced gastric adenocarcinoma with NAIC (NCT05515796). Correlation between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39495175
DOI: 10.1158/1078-0432.ccr-24-2436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II TrialPMID 39495175Read ↗

Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA VaccinationSemantic proximity Read ↗

Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification.Semantic proximity Read ↗

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor immune microenvironment in advanced gastric cancer: A phase II chemoimmunotherapy trialSemantic proximity Read ↗

MOLECULAR STRATIFICATION OF INTESTINAL AND DIFFUSE SUBTYPES OF GASTRIC ADENOCARCINOMA AND ITS PROGNOSTIC IMPACTSemantic proximity Read ↗

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor microenvironment in advanced gastric cancer: a phase II chemoimmunotherapy trialSemantic proximity Read ↗

Classification based on tumor phenotypes enables the novel molecular characterization of esophagogastric junction cancer.Semantic proximity Read ↗

Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric CancerSemantic proximity Read ↗

Identification of Tumor Antigens and Design of mRNA Vaccine for Colorectal Cancer Based on the Immune SubtypeSemantic proximity Read ↗

Comparative Analysis of Clinical Outcomes Between Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective StudySemantic proximity Read ↗

Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinomaSemantic proximity Read ↗

Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.Semantic proximity Read ↗

Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.